
CLGN Stock Forecast & Price Target
CLGN Analyst Ratings
Bulls say
CollPlant Biotechnologies Ltd demonstrates a robust growth trajectory fueled by its innovative rhCollagen-based products, particularly the Collink.3D bioink, which has shown superior properties in tissue engineering compared to traditional options. The operational launch of a U.S.-based logistics center is anticipated to enhance sales of BioInk and rhCollagen, especially as adoption increases among research institutions and customers in the tissue-engineering sector. With its strategic partnerships and ongoing advancements in regulatory approvals for products like the photocurable dermal filler, the company is poised for significant market adaptability and revenue growth within the regenerative and aesthetic medicine fields.
Bears say
CollPlant Biotechnologies Ltd's recent $2.0 million registered direct financing, priced at $1.25 per share, indicates sustained equity pressure and highlights the company's difficulties in capital formation amidst a challenging market environment. The decision to lower expectations for products such as Dermal Fillers and BioInk, alongside the removal of Breast Implants from financial models, reflects a weakening outlook for key revenue-generating segments. This combination of factors has raised concerns about investor confidence, potentially exacerbating a downward spiral in valuation.
This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.
CLGN Analyst Forecast & Price Prediction
Start investing in CLGN
Order type
Buy in
Order amount
Est. shares
0 shares